Boston Scientific Corp financial data

Symbol
BSX on NYSE
Industry
Surgical & Medical Instruments & Apparatus
Location
300 Boston Scientific Way, Marlborough, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 1, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 152 % +8.57%
Quick Ratio 48.8 % -3.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.47B shares +0.6%
Entity Public Float 79B USD
Common Stock, Value, Issued 17M USD 0%
Weighted Average Number of Shares Outstanding, Basic 1.47B shares +0.56%
Weighted Average Number of Shares Outstanding, Diluted 1.49B shares +0.84%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 15.9B USD +15.7%
Operating Income (Loss) 2.51B USD +16.2%
Nonoperating Income (Expense) -311M USD -9.12%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 2.2B USD +17.4%
Income Tax Expense (Benefit) 414M USD -36.1%
Earnings Per Share, Basic 1.23 USD/shares +50%
Earnings Per Share, Diluted 1.21 USD/shares +47.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.5B USD +163%
Inventory, Net 2.75B USD +14.5%
Other Assets, Current 674M USD -9.04%
Assets, Current 8.76B USD +34.7%
Deferred Income Tax Assets, Net 3.82B USD -0.63%
Property, Plant and Equipment, Net 3.07B USD +16.6%
Operating Lease, Right-of-Use Asset 426M USD -4.48%
Intangible Assets, Net (Excluding Goodwill) 5.75B USD -1.62%
Goodwill 15B USD +10.5%
Other Assets, Noncurrent 1.64B USD +2.31%
Assets 38.1B USD +11.9%
Accounts Payable, Current 907M USD -2.37%
Employee-related Liabilities, Current 1.11B USD +21.8%
Accrued Liabilities, Current 2.46B USD +9.09%
Liabilities, Current 5.91B USD +29.1%
Long-term Debt and Lease Obligation 9.23B USD +10.1%
Accrued Income Taxes, Noncurrent 364M USD -25.3%
Deferred Income Tax Liabilities, Net 138M USD +51.6%
Operating Lease, Liability, Noncurrent 373M USD -6.75%
Other Liabilities, Noncurrent 1.84B USD -0.92%
Accumulated Other Comprehensive Income (Loss), Net of Tax -128M USD -155%
Retained Earnings (Accumulated Deficit) 2.11B USD +569%
Stockholders' Equity Attributable to Parent 20.7B USD +9.65%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 21B USD +9.55%
Liabilities and Equity 38.1B USD +11.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 164M USD -13.7%
Net Cash Provided by (Used in) Financing Activities 1.57B USD
Net Cash Provided by (Used in) Investing Activities -285M USD +41.1%
Common Stock, Shares Authorized 2B shares 0%
Common Stock, Shares, Issued 1.73B shares +0.49%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.44B USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.65B USD +134%
Deferred Tax Assets, Valuation Allowance 1.22B USD +21.5%
Deferred Tax Assets, Gross 3.71B USD -2.42%
Operating Lease, Liability 466M USD +14.2%
Depreciation 394M USD +10.1%
Payments to Acquire Property, Plant, and Equipment 179M USD +61.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 1.45B USD +59.2%
Lessee, Operating Lease, Liability, to be Paid 539M USD +9.55%
Property, Plant and Equipment, Gross 6.69B USD +10.1%
Operating Lease, Liability, Current 76M USD +24.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure +30.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 74M USD -11.9%
Deferred Tax Assets, Operating Loss Carryforwards 744M USD +45.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Unrecognized Tax Benefits 493M USD +3.79%
Amortization of Intangible Assets 839M USD +2.32%
Depreciation, Depletion and Amortization 304M USD +6.67%
Deferred Tax Assets, Net of Valuation Allowance 3.81B USD -3.57%
Interest Expense 289M USD +9.06%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%